Literature DB >> 16296874

Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters.

Sofia K Kasiakou1, Kenneth R Lawrence, Nicolaos Choulis, Matthew E Falagas.   

Abstract

We performed a systematic review of randomised clinical trials to evaluate the comparative pharmacokinetic and pharmacodynamic properties of the continuous versus intermittent mode of intravenous administration of various antibacterials. Data were identified from PubMed (January 1950 to January 2005), Current Contents, the Cochrane central register of controlled trials, and references from relevant articles and reviews. Seventeen randomised clinical trials comparing continuous with intermittent intravenous administration of the same antibacterial regimen and examining the pharmacokinetic and pharmacodynamic properties were included in this systematic review. We reviewed data regarding the clinical setting, number of participants, antibacterial agents and dosages used, as well as maximum serum concentration (Cmax), trough serum concentration (Cmin), steady-state or plateau serum concentration (Css), area under the concentration-time curve (AUC), time above the minimum inhibitory concentration (MIC) [T>MIC], AUC: MIC, elimination rate constant, elimination half-life, volume of distribution and systematic clearance. The mean Cmax of the intermittently administered antibacterials was higher compared with Css achieved by the continuous infusion of the same antibacterial in all eligible studies (Cmax was on average 5.5 times higher than Css, range 1.9-11.2). Css was on average 5.8 times higher than the Cmin of the intermittently administered antibacterials (range 1.2-15.6). In three of six studies the length of time that the drug concentration was above the MIC of the responsible pathogens was longer in patients receiving the antibacterials continuously. In conclusion, the reviewed data suggest that the continuous intravenous infusion of antibacterials with time-dependent bacterial killing seems to be superior than the intermittent intravenous administration, from a pharmacodynamic point of view, at least when treating bacteria with high MIC values for the studied antibacterials.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16296874     DOI: 10.2165/00003495-200565170-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  83 in total

1.  Assessment of cefazolin and cefuroxime tissue penetration by using a continuous intravenous infusion.

Authors:  J E Connors; J T DiPiro; R G Hayter; K D Hooker; J A Stanfield; T R Young
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection.

Authors:  A Di Filippo; A R De Gaudio; A Novelli; E Paternostro; C Pelagatti; P Livi; G P Novelli
Journal:  Chemotherapy       Date:  1998 Jan-Feb       Impact factor: 2.544

3.  Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion.

Authors:  D S Burgess; R W Hastings; T C Hardin
Journal:  Clin Ther       Date:  2000-01       Impact factor: 3.393

4.  Serum concentrations of cefuroxime after continuous infusion in coronary bypass graft patients.

Authors:  S E Pass; C I Miyagawa; D P Healy; T D Ivey
Journal:  Ann Pharmacother       Date:  2001-04       Impact factor: 3.154

5.  Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children.

Authors:  I Rappaz; L A Decosterd; J Bille; M Pilet; N Bélaz; M Roulet
Journal:  Eur J Pediatr       Date:  2000-12       Impact factor: 3.183

6.  Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.

Authors:  A S Benko; D M Cappelletty; J A Kruse; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

7.  Tissue concentrations of mezlocillin in benign hypertrophy of the prostate following intravenous bolus injection versus infusion.

Authors:  K G Naber; D Adam
Journal:  J Antimicrob Chemother       Date:  1983-05       Impact factor: 5.790

8.  Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis.

Authors:  G L Drusano; D E Johnson; M Rosen; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

9.  Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis.

Authors:  M E Klepser; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Pharmacotherapy       Date:  1998 Sep-Oct       Impact factor: 4.705

10.  Administration of gentamicin and ampicillin by continuous intravenous infusion to newborn infants during parenteral nutrition.

Authors:  H Colding; G E Andersen
Journal:  Scand J Infect Dis       Date:  1982
View more
  10 in total

1.  Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases.

Authors:  K de With; F Allerberger; S Amann; P Apfalter; H-R Brodt; T Eckmanns; M Fellhauer; H K Geiss; O Janata; R Krause; S Lemmen; E Meyer; H Mittermayer; U Porsche; E Presterl; S Reuter; B Sinha; R Strauß; A Wechsler-Fördös; C Wenisch; W V Kern
Journal:  Infection       Date:  2016-06       Impact factor: 3.553

Review 2.  Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics.

Authors:  Kevin J Downes; Andrea Hahn; Jason Wiles; Joshua D Courter; Alexander A Vinks
Journal:  Int J Antimicrob Agents       Date:  2013-12-17       Impact factor: 5.283

Review 3.  Use of pharmacodynamic principles to optimise dosage regimens for antibacterial agents in the elderly.

Authors:  Ayman M Noreddin; Virginia Haynes
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 4.  Pharmacokinetics and pharmacodynamics of antibacterial agents.

Authors:  Matthew E Levison; Julie H Levison
Journal:  Infect Dis Clin North Am       Date:  2009-12       Impact factor: 5.982

5.  Risk factors for target non-attainment during empirical treatment with β-lactam antibiotics in critically ill patients.

Authors:  Jan J De Waele; J Lipman; M Akova; M Bassetti; G Dimopoulos; M Kaukonen; D Koulenti; C Martin; P Montravers; J Rello; A Rhodes; A A Udy; T Starr; S C Wallis; J A Roberts
Journal:  Intensive Care Med       Date:  2014-07-23       Impact factor: 17.440

Review 6.  Meropenem: a review of its use in the treatment of serious bacterial infections.

Authors:  Claudine M Baldwin; Katherine A Lyseng-Williamson; Susan J Keam
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 7.  Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections.

Authors:  Jennifer Shiu; Erica Wang; Aaron M Tejani; Michael Wasdell
Journal:  Cochrane Database Syst Rev       Date:  2013-03-28

8.  Continuous beta-lactam infusion in critically ill patients: the clinical evidence.

Authors:  Mohd H Abdul-Aziz; Joel M Dulhunty; Rinaldo Bellomo; Jeffrey Lipman; Jason A Roberts
Journal:  Ann Intensive Care       Date:  2012-08-16       Impact factor: 6.925

Review 9.  Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis.

Authors:  Hui Yang; Chao Zhang; Quanyu Zhou; Yike Wang; Lujia Chen
Journal:  PLoS One       Date:  2015-01-09       Impact factor: 3.240

10.  Dose optimization of β-lactams antibiotics in pediatrics and adults: A systematic review.

Authors:  Abdul Haseeb; Hani Saleh Faidah; Saleh Alghamdi; Amal F Alotaibi; Mahmoud Essam Elrggal; Ahmad J Mahrous; Safa S Almarzoky Abuhussain; Najla A Obaid; Manal Algethamy; Abdullmoin AlQarni; Asim A Khogeer; Zikria Saleem; Muhammad Shahid Iqbal; Sami S Ashgar; Rozan Mohammad Radwan; Alaa Mutlaq; Nayyra Fatani; Aziz Sheikh
Journal:  Front Pharmacol       Date:  2022-09-21       Impact factor: 5.988

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.